BriaCell presents anti-cancer activity of Bria-OTS

BriaCell (BCTX) Therapeutics is presenting “positive” data from its preclinical Bria-OTS+ platform at the 2026 American Association for Cancer Research, AACR, Annual Meeting taking place April 17-22 at the San Diego Convention Center in San Diego, California. Title: Re-Engineering Cancer Vaccines: Bria-OTS+ Integrates Innate and Adaptive Immunity for Broad and Persistent Anti-Tumor Responses. Summary: Bria-OTS+ is a personalized, off-the-shelf, next-generation genetically engineered whole-cell cancer immunotherapy platform designed to enhance efficacy and safety. Results demonstrate that Bria-OTS+ activates key components of both the innate and adaptive immune systems to broadly target and destroy cancer cells across solid tumors. These effects include coordinated activation of CD4 and CD8 T cells, NK cells, NKT cells, dendritic cells, and B cells, together with increased cytokine release and sustained immune competence without exhaustion-helping address an important mechanism of cancer progression.